Frontiers in Peritoneal Dialysis

Front Matter....Pages i-x
Front Matter....Pages 1-1
The Ultrastructure of the Parietal Peritoneum in Normal and Uremic Man and in Patients on CAPD....Pages 3-10
The Morphology of the Peritoneum in CAPD Patients....Pages 11-19
Fenestrated Capillaries in the Human Parietal Peritoneum and Rabbit Diaphragmatic Peritoneum....Pages 20-23
Lymph Flow from the Peritoneal Cavity in CAPD Patients....Pages 24-30
A Distributed Model of Peritoneal Transport....Pages 31-36
Maximal Peritoneal Pore Size Determined by Dextran Transport....Pages 37-40
Peritoneal Absorption of Macromolecules....Pages 41-46
Peritoneal Membrane Permeability for High and Low Molecular Weight Proteins (H/LMWP) in CAPD....Pages 47-52
Follow-up of Peritoneal Mass Transfer Properties in Long-term CAPD Patients....Pages 53-55
Dependence of Middle Molecular Clearance on Protein Concentration of Peritoneal Fluid....Pages 56-63
An International Survey of Ultrafiltration in CAPD....Pages 64-67
Changes in Ultrafiltration and Solute Transport During CAPD....Pages 68-74
Prediction of Changes in Transperitoneal Water Transport During CAPD—A Prospective Study....Pages 75-81
Influence of Blood Flow and Plasma Proteins on UF Rate in Peritoneal Dialysis....Pages 82-87
Prognostic Value of Peritoneal Equilibration Curves in CAPD Patients....Pages 88-93
Role of Peritoneal Membrane Hydration in UF Capacity of Patients on CAPD....Pages 94-99
Studies on Peritoneal UF Loss: The UF Coefficient (K) as an Index of the PM Filtration Efficiency....Pages 100-105
Increased Peritoneal Ultrafiltration Due to Amphotericin B Augmented Sodium Transport....Pages 106-109
Serum Concentration and Peritoneal Transfer of Aluminum during Treatment by CAPD....Pages 110-116
Calcium Peritoneal Mass Transfer in CAPD....Pages 117-121
Front Matter....Pages 1-1
Changes in Plasma Protein Spectra after IP Injection of Hypertonic and Isotonic Solutions....Pages 122-124
Pharmacokinetics of Cefotaxime during CAPD....Pages 125-130
Multiple Dose IP Vancomycin Kinetics during CAPD....Pages 131-134
IP Administration of Moxalactam during CAPD....Pages 135-140
Front Matter....Pages 141-141
Experimental and Clinical Origins of Peritoneal Dialysis for Renal Failure....Pages 143-147
The Sorbent Suspension Reciprocating Dialyzer for Use in Peritoneal Dialysis....Pages 148-156
Application of Antibiotic Bonding to CAPD Catheters....Pages 157-160
Clinical Experience in CAPD Using Flame-Lock Connecting Device: A Group Study....Pages 161-165
Intraluminal Thermosterilization Using a Microwave Autoclave....Pages 166-168
The Ultraviolet Germicidal System: The Elimination of Distal Contamination in CAPD....Pages 169-175
Biofilm on Tenckhoff Catheters: A Possible Source for Peritonitis....Pages 176-180
CAPD: One Cuff vs Two Cuff Catheters in Reference to Incidence of Infection....Pages 181-182
Profound Reduction in Peritonitis in CAPD Using Travenol System IIR Connectors and Betadine....Pages 183-189
CAPD Peritonitis and Different Connecting Devices: A Statistical Comparison....Pages 190-192
Clinical Application of a Miniaturized Variant of the Perugia CAPD Connection System....Pages 193-197
Peritonitis Prevention in CAPD: Efficacy of a Y-Connector and Disinfectant....Pages 198-202
Long-Term Use of Unidirectional Bacteriologic Filters to Reduce Peritonitis Frequency in CAPD....Pages 203-206
Skin Reaction Against the Catheter: An Explanation for Exit Site Infection in CAPD....Pages 207-209
Elimination of Tunnel Infection....Pages 210-217
Successful Peritoneal Catheter Placement after Major Abdominal Surgery or Peritonitis....Pages 218-222
Front Matter....Pages 141-141
Reduction of Complications with Bedside Lateral Placement of Catheter for CAPD....Pages 223-224
Microcomputer Peritoneal Programmer in Service of Acute Peritoneal Dialysis....Pages 225-230
A Comparison of Glucose Polymer and Dextrose as Osmotic Agents in CAPD....Pages 231-240
Glucose Polymer As an Osmotic Agent in CAPD....Pages 241-248
Sustained UF with Gelatin Dialysis Solution during Long Dwell Dialysis Exchanges in Rats....Pages 249-254
Glycerol Instead of Dextrose As an Osmotic Agent in CAPD....Pages 255-260
Potentially Irritant Glucose Metabolites in Unused CAPD Fluid....Pages 261-264
CAPD Using a High Calcium Concentration....Pages 265-269
Is Peritoneal Ultrafiltration Influenced by Acetate or Lactate Buffers?....Pages 270-273
Evolution of Ultrafiltration in CAPD According to the Dialysis Fluid Buffer....Pages 274-278
Comparison of Different Volume Markers in Peritoneal Dialysis....Pages 279-282
Critical Evaluation of the Injection Site for Insulin in CAPD for Diabetic Patients....Pages 283-287
Front Matter....Pages 289-289
Overview of Three Year Experience of the National CAPD Registry of the National Institutes of Health....Pages 291-292
Multi-center Study on the Outcome of Patients on CAPD and Hemodialysis....Pages 293-296
CAPD in Italy: A Multicenter Study....Pages 297-303
Is CAPD a Second Class Treatment?....Pages 304-306
CAPD and Protein-Permeating Hemodialysis: A Clinical Comparison....Pages 307-311
CAPD in the Elderly—Regional Experience....Pages 312-317
Italian Multicentric Study on Diabetic Uremic Patients Treated by CAPD....Pages 318-322
CAPD in the Diabetic; Comparison with Nondiabetics on CAPD....Pages 323-328
Front Matter....Pages 289-289
CAPD in Infants....Pages 329-333
Outcome of High Risk Patients on CAPD....Pages 334-336
Four Year Experience in CAPD....Pages 337-340
Prognostic Correlates in Ambulatory Peritoneal Dialysis Versus Hemodialysis....Pages 341-346
Peritoneal Dialysis for In-Hospital Patients....Pages 347-352
Renal Transplantation in Patients on CAPD....Pages 353-356
Hemodialysis Requirements of CAPD Patients....Pages 357-359
Home CAPD Nurse—An Asset to a CAPD Program....Pages 360-363
The Telephone—An Underestimated Resource for CAPD Nursing Management....Pages 364-365
Psychological and Economic Assessment of Peritoneal Dialysis Patients in Nigeria....Pages 366-367
CAPD on Alternate Days....Pages 368-372
Low BUN: A Negative Prognostic Indicator Early in CAPD....Pages 373-377
Two Years Experience with High Volume Low Frequency CAPD....Pages 378-381
Successful Use of CAPD in Refractory Heart Failure....Pages 382-386
Front Matter....Pages 387-387
Nutritional Requirements with CAPD....Pages 389-399
Muscle Free Amino Acids in Patients Treated with CAPD....Pages 400-404
Total Body Potassium and Fat Free Mass in CAPD....Pages 405-408
Effect of Increased Insulin Secretion during CAPD on Potassium Metabolism....Pages 409-415
Amino Acid Versus Glucose Dialysis in Children on CAPD....Pages 416-420
Nutritional Aspects in Children on CAPD....Pages 421-428
Front Matter....Pages 387-387
Intraperitoneal Versus Oral Glucose Load in CAPD Patients....Pages 429-431
The Effect of CAPD on Lipid Abnormalities Detected by Apoproteins and Ultracentrifugal Lipid Subfractions....Pages 432-436
Post-Heparin Lipolytic Enzymes in Patients on CAPD....Pages 437-442
Body Composition in Uremic Children on CAPD and Hemodialysis....Pages 443-445
Protein and Amino Acid Losses from the Peritoneum during CAPD and CCPD....Pages 446-449
Blood Pressure on CAPD: Relationship to Sodium Status, Renin, and Aldosterone, Compared with Hemodialysis....Pages 450-456
Influence of Hypertension on Vision in Diabetics Undergoing Dialysis: Comparison of Peritoneal and Hemodialysis....Pages 457-463
Bone Histomorphometry during Long-Term CAPD....Pages 464-470
Effect of CAPD on Renal Osteodystrophy in Unmodified Patients Moving from Hemodialysis to CAPD....Pages 471-477
The Trace Elements B r , C o , C r , C s , C u , F e , M n , R b , S e and Z n in Serum, Packed Cells, and Dialysate of CAPD Patients....Pages 478-481
High Muscle Magnesium and Potassium in Long-Term Regular Dialysis Treatment....Pages 482-485
Respiratory Function in CAPD....Pages 486-490
Effect on Erythropoiesis of Normal Monocytes and Peritoneal Macrophages from CAPD Patients....Pages 491-498
Creatine Kinase, Amylase, and Parathyroid Hormone in Stable CAPD and Hemodialysis Patients....Pages 499-503
CK Isoenzymes in CAPD and Hemodialysis Patients....Pages 504-507
Total CK and CK-MB Elevation in Dialysis Patients without Acute Myocardial Infarction....Pages 508-511
Sexual Dysfunction in Patients Treated by CAPD....Pages 512-515
Front Matter....Pages 517-517
Prognostic Indicators of Hernia Development in Patients Undergoing CAPD....Pages 519-520
Peritoneal Catheter Perforating into the Colon—A Serious Complication of Peritoneal Dialysis....Pages 521-523
CAPD, a Permanent State of Peritonitis: A Study on Peroxidase Activity....Pages 524-530
Front Matter....Pages 517-517
A 3 1/2 Year Experience with Peritonitis in Children Undergoing CAPD and CCPD....Pages 531-535
Incidence of Peritonitis and Delayed-Type Hypersensitivity in Patients on CAPD....Pages 536-541
The Importance of Iron for Bacterial Growth in Peritoneal Dialysis Fluid....Pages 542-545
The Importance of Intracellular Organisms in CAPD....Pages 546-549
Immunologic Pattern in CAPD Patients with Low or High Peritonitis Incidence....Pages 550-558
Defective Complement-Mediated Opsonization and Lysis of Bacteria in Commercial Peritoneal Dialysis Solutions....Pages 559-564
Opsonizing Capacity of Peritoneal Fluid and Relationship to Peritonitis in CAPD Patients....Pages 565-568
Opsonization Capacity of Plasma and Peritoneal Dialysate in CAPD Patients....Pages 569-572
Opsonically-Active Proteins in CAPD Fluid....Pages 573-578
Defective Peritoneal Polymorphonuclear Leukocyte Function in Patients on Intermittent Peritoneal Dialysis: Effects of Some Divalent Ions and Fibronectin....Pages 579-582
Surface Marker Characterization of Peritoneal Dialysis Patients’ Intraperitoneal Leukocytes by Monoclonal Antibodies....Pages 583-585
HLA Markers and Peritonitis in CAPD Patients....Pages 586-590
Comparison of Lymphocyte Markers and Lymphoblastic Transformation Studies of Patients Converted from Hemodialysis to CAPD....Pages 591-596
T Lymphocytes Subsets in CAPD and Hemodialysis (HD) Patients: A Prospective Study....Pages 597-599
Immunoglobulins in CAPD....Pages 600-603
Enhanced Peritoneal Generation of Vasoactive Prostaglandins during Peritonitis in Patients Undergoing CAPD....Pages 604-609
Thromboxane and Prostaglandin Synthesis in Human Peritoneal Eosinophils....Pages 610-612
A Comparison of the Stimulatory Effects of Prostaglandins on Human and Rat Peritoneal Macrophage cAMP Synthesis....Pages 613-615
Alteration in Glucose Absorption During Peritonitis and Its Effects in Diabetic and Nondiabetic Patients Undergoing CAPD....Pages 616-618
Suitability of Povidone-lodine Formulations for CAPD....Pages 619-624
Front Matter....Pages 517-517
No Difference Between Oral and Intraperitoneal Treatment of CAPD Peritonitis with Cephradine....Pages 625-629
Hazards of CAPD: Interleukin-1 Production....Pages 630-633
Sclerosing Encapsulating Peritonitis and Other Complications of CAPD Peritonitis....Pages 634-637
Sclerosing Peritonitis—A Further Complication of CAPD....Pages 638-642
Sclerosing Encapsulating Peritonitis during CAPD. Evaluation of the Potential Risk Factors....Pages 643-649
Back Matter....Pages 651-662